Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agreed;
Lets hope something is coming down the pipe......otherwise dept financing....not good.
This Tar-1 Licensing agreement seems promising due to the nature of the payments....big payments mean big revenue. And to have actual monetary figures, instead of percentage values, gives me the notion that this compound may be coming to fruition.
Could be wrong......
Beaner
As for Burkett...who knows....who cares....this guy was a mid level captain anyways.....Interesting on who will replace him....maybe a little higher profile CEO.
Nothing really new, except this......
This is very Promising......
Note 5. Licensing agreements
TAR-1 license agreement
In October 2009, the Company entered into a license agreement with an Israeli company for world-wide rights to develop and commercialize a transactivation and apoptosis restoring (TAR-1) developmental drug candidate. The Company may terminate the license agreement in whole or in part on a country by country basis for any reason upon sixty days prior written notice.
Under the terms of the agreement, the Company will make an initial payment of $60,000 upon execution of the agreement. In addition, the Company will be required to pay $6,140,000 upon successful completion of certain clinical milestones, $5,000,000 upon reaching certain regulatory approvals and $23,000,000 upon achievement of certain commercial milestones. The Company will also make royalty payments based on net sales as defined in the license agreement. In addition, the Company will pay an annual licensing fee of $30,000 for the first three years of the agreement beginning on the second year of the agreement. The Company also agreed to pay for $118,000 of past patent expenses incurred by the Israeli company prior to execution of the agreement. The initial payment of past patent expenses, first annual licensing fee and initial payment were all charged to research and development expense during the three months ended October 31, 2009.
10Q due any day now -e-
However you are mostly correct. The benefits of the NOL's have reduced as they are severely restricted.
With a Change of control..... the NOL's are now a percentage of the value of the shell. Which was sold for $8000.....Otherwise useless.
Interesting what Acorda may be up to though, lots happening....Rochlin is just a puppet......
It can if the the merging entity is new or spunoff from an existing company.
Bartly J. Loethen
Synery Law Group founding partner......he is the one that took control of Wincroft and Forme Captial from DW and Merged them with two companies from China
Looks like Bartly has is hands on this one as well........
I will believe it when I see it X!!
No lawsuits, tax loss carryforward....
Huey, Dewy and Loui seem to be in a row......but Loui....I heard is lame.....
Beaner
Nice
Another Johnson and Johnson company.......
Agreed. Eom
If he does I am sure we will find out.....if not....... Tick, Tick,Tick.............Boom.............
Regards;
Brent
Yes it was bee.....
Absolutely Criminal!! -e-
Good Morning to you to Bee!!
Ciao for now.....
Cash is King right now Bee. The Smart Ones see an opportunity from this though.
POUNDED!!
And only going to get worse!
Because it is suspended from trading by the SEC, as of September 30th.
http://www.sec.gov/litigation/suspensions.shtml
Agreed Jdoo.
WOW!
Burkett bought 1500 shares at a buck on the open market yesterday!! LOL!
I think he is talking about Bristol Myers buying out Imclone.
Imo it doesn't really matter, Bristol Myers will be on board in due time anyway.
Not due until end of July....
I am wondering jdoo, if this platform has the ablility to eliminate that exhausting time frame. In the FDAs critical path program, it states that eliminating that time frame, and getting good, effective drugs to the market faster is their main goal.
It seems to me that Champions, if you can read between the lines, could be eliminating a "step" if you will. If you can effectively predict a Phase 2 outcome in the preclinical stage,
that shaves years off a drug candidates journey to market.
Anyone notice the transaction Date on the Form 5. Could be a typo.
Annual Report my friend!!!
I have a feeling July is going to be a very memorable month for us.
Cheers;
Beaner17
I was thinking the same thing...onward and upward!!! As Jdoo said in a previous post, hopefully this is additional to the 924,000 last reported in the 10q.
Nice to hear from you Super, do you think this a new Service Agreement or the same one in the 10Q?
News...
Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
ARLINGTON, Va., May 6 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, announced today the completion of a Service Agreement with Concordia Pharmaceuticals, Inc. and initiation of preclinical studies to evaluate new applications for Salirasib using Champions Biotechnology's Biomerk Tumorgrafts(TM).
'Our Biomerk Tumorgraft preclinical platform and its benefits in drug discovery and evaluation is gaining recognition as we expand our platform to pharmaceutical and biotech companies' said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. 'Champions is in a unique position to evaluate oncology drugs as well as novel drug combinations that may be effective in treating specific cancer types. We are pleased to be assisting Concordia Pharmaceuticals in the evaluation of new preclinical applications for Salirasib, a Ras-antagonist that acts to inhibit cancer by impairing the disease's ability to replicate defective cells.'
For more information regarding Champions Biotechnology's growing business and recent news, please visit www.championsbiotechnology.com.
About Champions Biotechnology, Inc.
Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. The Company believes that these Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients.
Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care. In the course of this process, this permits the Company to evaluate oncology drugs for companies by using models that integrate prognostic testing with biomarker discovery.
Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.
This press release contains 'forward-looking statements' (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as 'believe,' 'may,' 'could,' 'will,' 'intend,' 'expect,' 'anticipate,' 'plan,' and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Biotechnology's Form 10-KSB for the fiscal year ended April 30, 2007 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Biotechnology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Biotechnology's expectations, except as required by law.
SOURCE Champions Biotechnology
Source: PR Newswire (May 6, 2008 - 8:31 AM EDT)
News by QuoteMedia
www.quotemedia.com
This is true corporate governance.
The company stated in the last press release that they are intending on adding Independent Officers to their state of the art corporate governance regime. That is why Martell, and Settles, resigned as well. Martells new title cites the work he has been doing with Sidransky for years.
The facts say that the two major holders of this stock are Hidalgo and Sidransky.
If anyone has had a careful look at the new website, you will see 4 different revenue streams this company is capable of generating from. In my opinion, Sidranskys' platform could change the way physicians treat cancer patients. I will let you do your own due diligence on those.
As for Hidalgo, one of those revenue streams is why he owns a majority in this company and why he is the CSO.
Relax and be well folks, something very special is unfolding here.
Cheers;
beaner17
If anyone has read the 10q, there is some interesting info as to where this company is headed in the next year...... all I have to say is....impressive.
You have to wonder when Sidransky and Hidalgo are going to unleash this puppy.
I don't know if this has been posted, but Hidalgo and Kahns patent app is available for viewing at WIPO for anyone who is interested.
http://www.wipo.int/patentscopedb/en/fetch.jsp?LANG=ENG&DBSELECT=PCT&SERVER_TYPE=19-10&SORT=1213192-KEY&TYPE_FIELD=256&IDB=0&IDOC=1393973&C=10&ELEMENT_SET=B&RESULT=13&TOTAL=67&START=1&DISP=25&FORM=SEP-0/HITNUM,B-ENG,DP,MC,AN,PA,ABSUM-ENG&SEARCH_IA=US2006014449&QUERY=%28PA%2fhidalgo%29+
Caml
0.015 (5000 shares) 0.03 (5000 shares)
Wow...Huge Gap.... 105 x 140
Looking good this am, I love the way this moves....News is due....Lets hope Superbee
How Low will she go!! I guess the news of Sidransky becoming Chairman of ACEL didn't bode well with investors of CSBR. Interesting to say the least. This thing is in a spiral, we could see 90 cents today, good buying oppourtunity IMO.
Been there, done that!! Have a great day!
I see... that filing was put out on December 7th. It is over a month old.
Cheers;
Brent
Forgive me, but I don't quite understand the relevence of your post. Could you please explain?